Oropharyngeal Cancer Clinical Trial
Official title:
Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135]
This phase I/II trial is studying the side effects and best dose of gene therapy and to see how well it works in preventing cancer in patients with premalignant carcinoma of the oral cavity or pharynx. Inserting the p53 gene into a person's tumor cells may improve the body's ability to kill the tumor cells
OBJECTIVES:
I. Determine the acute toxic effects of Ad5CMV-p53 gene administered as an oral rinse and as
an intramucosal injection in patients with diffuse premalignant carcinoma of the oral cavity
or oral pharynx.
II. Determine the maximum tolerated dose of this drug in these patients. III. Determine the
topical transduction efficiency of adenoviral-mediated wild type p53 gene transfer in
patients treated with this drug.
IV. Determine the efficacy of this drug in reversing the histology of oral premalignancies
in these patients.
V. Determine the distribution of transgenic protein within the area of the premalignant
lesion in patients treated with this drug.
OUTLINE: This is an open-label, dose-escalation study of Ad5CMV-p53 gene administered as an
oral rinse.
Phase I: Patients receive Ad5CMV-p53 gene by intramucosal injection into the area of the
lesion followed at least 2 hours later by Ad5CMV-p53 gene as an oral rinse on day 1.
Patients then receive Ad5CMV-p53 gene as an oral rinse twice daily on days 2-5. Treatment
repeats every 28 days for 6 courses in the absence of disease progression or unacceptable
toxicity. Cohorts of 3-6 patients receive escalating doses of Ad5CMV-p53 gene as an oral
rinse until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose
preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Phase II: Patients receive treatment with intramucosal Ad5CMV-p53 gene as in phase I and
Ad5CMV-p53 gene as an oral rinse at the MTD. Patients are followed every 3 months for 1
year, every 6 months for 1 year, and then annually for 3 years. Patients then receive
long-term follow-up annually for an additional 10 years.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03656133 -
Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers
|
N/A | |
Terminated |
NCT02225496 -
Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
|
Phase 2 | |
Withdrawn |
NCT01767961 -
Modified Barium Swallow in Measuring Swallowing Function After Surgery in Patients With Oropharyngeal Cancer
|
N/A | |
Completed |
NCT01695122 -
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01435252 -
A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab
|
Phase 2 | |
Recruiting |
NCT04708470 -
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00951470 -
Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema
|
N/A | |
Completed |
NCT01358097 -
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
|
N/A | |
Completed |
NCT01342978 -
Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time
|
N/A | |
Completed |
NCT00964977 -
Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.
|
Phase 3 | |
Recruiting |
NCT05363709 -
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
|
Phase 2 | |
Completed |
NCT02280811 -
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
|
Phase 2 | |
Active, not recruiting |
NCT03777384 -
EValuating the Safety Of De-escaLated Head and Neck Irradiation in HPV positivE Oropharynx Cancer in Non-smokers/Minimal Smokers
|
||
Active, not recruiting |
NCT03729518 -
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
|
N/A | |
Recruiting |
NCT06121102 -
Standard Pulsed Radiofrequency Versus Supervoltage Pulsed Radiofrequency Glossopharyngeal Nerve in Oropharyngeal Cancer Pain
|
N/A | |
Recruiting |
NCT02984410 -
Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma
|
N/A | |
Recruiting |
NCT02960724 -
uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer
|
Phase 2 | |
Completed |
NCT02934724 -
Impact of HPV Vaccine On The Prevalence Of HPV In Norway
|
||
Withdrawn |
NCT00928161 -
Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy
|
N/A | |
Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|